Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MetaGuideX Ltd logo — Developing New Early Cancer Diagnostics and Treatments, givi...

MetaGuideX Ltd

Developing New Early Cancer Diagnostics and Treatments, giving Novel Insights into Decisions on Patients.

Founded 2020 United Kingdom Oxford, United Kingdom 3 employees Biotechnology, Health Care

General Information

Company Name MetaGuideX Ltd
Founded Year 2020
Location United Kingdom Oxford, United Kingdom
Employees 3
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with MetaGuideX Ltd. To contact MetaGuideX Ltd, visit metaguidex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MetaGuideX Ltd compare?

A PDF of MetaGuideX Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MetaGuideX Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MetaGuideX Ltd

MetaGuideX Ltd is a United Kingdom-based startup focused on the development of new early cancer diagnostics and treatments. Their slogan, "Developing New Early Cancer Diagnostics and Treatments, giving Novel Insights into Decisions on Patients," reflects their mission to provide better decisions on patient referrals in primary care, ultimately aiming to save lives and assist pharmaceutical companies in accessing patients earlier. The company offers a low-cost assay capable of detecting multiple early-stage cancers from just one milliliter of blood. This breakthrough technology has the potential to revolutionize cancer diagnosis and treatment decision-making processes. Since its founding in 2020, MetaGuideX Ltd has achieved significant milestones, including successful participation in three accelerator programs. As a result, the company has obtained clinical validation for its assay, positioning them for further growth and development. MetaGuideX Ltd also possesses additional novel intellectual property in its pipeline, targeting a broader range of disease indications and metastatic therapy. Notably, the company has achieved these milestones without relying on dilutive funds, highlighting their strategic approach to financial management. As of now, MetaGuideX Ltd has not disclosed its last investment or the involved investors. However, the company's innovative approach to early cancer diagnostics and treatments, along with its substantial progress in clinical validation, makes it an intriguing prospect for potential investors seeking opportunities in the biotechnology and healthcare industries. With a remarkable focus on addressing critical unmet needs in cancer care, MetaGuideX Ltd stands as a promising player in the healthcare startup landscape, offering compelling potential for both financial returns and societal impact.

Business keywords: early cancer diagnostics, treatment development, cancer assay, clinical validation, IP development, metastatic therapy, accelerator programmes, pharma access, patient referral, primary care, low-cost diagnostics, blood-based diagnostics, non-dilutive funding, novel insights, startup

No funding data available for MetaGuideX Ltd yet.

MetaGuideX Ltd Alternatives & Competitors

View All Alternatives
MetaGuideX Ltd vs
PreCyte Inc
PreCyte Inc United States

Envisioning a world free from cancer and neurodegenerative disease

3 employees
Biotechnology, Health Care
MetaGuideX Ltd vs
Immunicon
Immunicon

Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer ins...

Series F
Biotechnology, Health Care
MetaGuideX Ltd vs
OncoSwab
OncoSwab

Simplifying lung cancer detection.

Seed
7 employees
Biotechnology, Health Care
View all alternatives

FAQ About MetaGuideX Ltd

Developing New Early Cancer Diagnostics and Treatments, giving Novel Insights into Decisions on Patients.
MetaGuideX Ltd was founded in 2020.
MetaGuideX Ltd is headquartered in Oxford, United Kingdom.
MetaGuideX Ltd operates in Biotechnology and Health Care. Its work centres on early cancer diagnostics, treatment development, cancer assay and clinical validation.
MetaGuideX Ltd has approximately 3 employees.
Top alternatives and competitors to MetaGuideX Ltd include PreCyte Inc, Immunicon, OncoSwab, Creative BioTherapeutics LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MetaGuideX Ltd and PreCyte Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MetaGuideX Ltd, https://bouncewatch.com/company/metaguidex-ltd, updated 2 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout